Alnylam announces u.s. food and drug administration acceptance of new drug application for investigational vutrisiran for the treatment of the polyneuropathy of hereditary attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the u.s. food and drug administration (fda) has accepted the company's new drug application (nda) for vutrisiran, an investigational rnai therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hattr) amyloidosis in adults. the fda has set an action date of april 14, 2022 under the prescription drug user fee act (pdufa), a
ALNY Ratings Summary
ALNY Quant Ranking